Abstract

Melanoma is one of the most malignant and aggressive cancers with high cancer-related deaths. However, it is unclear whether Ku80 regulates tumor growth in human melanoma. In this study, we screened a siRNA library targeting 6024 human genes and identified Ku80 as a potential therapeutic target in melanoma cells. Knockdown of Ku80 significantly suppressed melanoma cell proliferation and induced apoptosis, as well as enhanced the antitumor effect of melatonin in melanoma in vitro and in vivo. Overexpression of Ku80, however, promoted melanoma growth and increased the insensitivity of melanoma cells to melatonin. Mechanistically, we found that Ku80 bound to the PDK1 promoter and activated the transcription of PDK1. Moreover, we showed that the binding of Ku80 at the PDK-1 promoter was HIF1-α dependent, and melatonin degraded HIF1-α in melanoma cells. Furthermore, clinical data revealed that the expression of Ku80 and PDK-1 proteins were positively correlated and elevated in the tumor tissues of melanoma patients, and high expression of Ku80 predicted a poor prognosis in melanoma. Collectively, our study demonstrated that Ku80 promoted melanoma growth and regulated antitumor activity of melatonin by targeting HIF1-α dependent PDK-1 signaling pathway, suggesting that Ku80 may be a potential molecular target for melanoma treatment.

Highlights

  • Melanoma is one of the leading causes of death from skin cancer, and its incidence is increasing globally [1]

  • We proved that melatonin synergize with Ku80 knockdown to inhibit cells growth through HIF1-α dependent Ku80/PDK1 pathway

  • To elucidate the molecular mechanism by which Ku80 regulated melanoma cell proliferation, we examined the expression and phosphorylation of key proteins in growth regulation, and found that knockdown of Ku80 repressed the phosphorylation of mTOR, PI3K, Akt and ERK (Fig. 2E)

Read more

Summary

Introduction

Melanoma is one of the leading causes of death from skin cancer, and its incidence is increasing globally [1]. While BRAF inhibitors have improved the overall response rates and survival compared to chemotherapy [11], their effect is short-term in most patients due to the development of resistance at a median of 5–7 months [5], even though their combination with MEK inhibitors has demonstrated benefit in progression free survival [12,13].

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.